Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $688000.0.

  • Day One Biopharmaceuticals' Change in Account Payables rose 12007.59% to $688000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 83823.53%. This contributed to the annual value of $686000.0 for FY2024, which is 7038.0% down from last year.
  • Day One Biopharmaceuticals' Change in Account Payables amounted to $688000.0 in Q3 2025, which was up 12007.59% from $2.6 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Change in Account Payables high stood at $4.4 million for Q1 2023, and its period low was -$3.7 million during Q4 2022.
  • For the 4-year period, Day One Biopharmaceuticals' Change in Account Payables averaged around $268933.3, with its median value being -$74000.0 (2023).
  • Examining YoY changes over the last 5 years, Day One Biopharmaceuticals' Change in Account Payables showed a top increase of 234864.86% in 2024 and a maximum decrease of 19190.8% in 2024.
  • Day One Biopharmaceuticals' Change in Account Payables (Quarter) stood at -$3.7 million in 2022, then skyrocketed by 78.05% to -$815000.0 in 2023, then skyrocketed by 130.06% to $245000.0 in 2024, then skyrocketed by 180.82% to $688000.0 in 2025.
  • Its Change in Account Payables was $688000.0 in Q3 2025, compared to $2.6 million in Q2 2025 and -$722000.0 in Q1 2025.